Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial-Reference-Cited by-同舟云学术

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial

Published:2023-06-29 Issue:10 Volume:25 Page:3064-3067
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Laursen Jens Christian¹^ORCID,Rotbain Curovic Viktor¹^ORCID,Kroonen Marjolein Y. A. M.²,Jongs Niels²,Zobel Emilie H.¹,Hansen Tine W.¹^ORCID,Frimodt‐Møller Marie¹,Laverman Gozewijn D.³,Kooy Adriaan⁴⁵,Persson Frederik¹,Heerspink Hiddo J. L.²^ORCID,Hansen Christian Stevns¹^ORCID,Rossing Peter¹⁶^ORCID

Affiliation:

1. Steno Diabetes Center Copenhagen Herlev Denmark

2. Department of Clinical Pharmacy and Pharmacology University of Groningen Groningen The Netherlands

3. Ziekenhuis Groep Twente Almelo The Netherlands

4. Bethesda Diabetes Research Center Hoogeveen The Netherlands

5. Department of Internal Medicine University of Groningen Groningen The Netherlands

6. University of Copenhagen Copenhagen Denmark

Funder

Novo Nordisk Fonden

Publisher

Wiley

Subject